https://doi.org/10.55788/be09c0b0
The current multicentre, open-label, phase 2 REACT trial (NCT02836574) included participants aged 30–80 years, with type 2 diabetes and stage 3–4 CKD (eGFR between ≥20 and <50 mL/min/1.73 m2), and without renal dialysis. Following baseline biopsy, participants were randomised to an active cohort (receiving 2 rilparencel doses immediately, n=39) or to a deferred group (receiving 2 rilparencel injections 12 months after baseline, n=34). The time between rilparencel doses was 3–6 months. All participants received background standard-of-care therapy. The primary efficacy endpoint was a change in kidney function determined by serial eGFR measurements [1].
The deferred cohort served as the control group for the active cohort for the initial 12 months of the trial. At 12 months after baseline and before the deferred start of rilparencel, the mean eGFR reduction was -3.7 mL/min/1.73 m2 in the active group compared with -4.3 mL/min/1.73 m2 in the deferred group (P<0.05). Upon the start of rilparencel, the deferred group’s eGFR stabilised, with a mean decline of -1.1 mL/min/1.73 m2. The significant differences were maintained in a post-hoc analysis in participants with eGFR < 30 ml/min/1.73 m2. In total, 3 serious adverse events (AEs) related to the biopsy and 10 AEs related to study injections were observed and none of them were linked to rilparencel. Non-serious AEs, potentially linked to rilparencel, included kidney fibrosis and indeterminate renal vessel occlusion/vasospasm.
“Our data suggest that rilparencel may preserve kidney function in patients with type 2 diabetes and moderate-to-severe chronic kidney disease”, said Dr Joseph Stavas (ProKidney LLC, Winston-Salem, NC, USA). “Rilparencel is under further investigation in an ongoing global phase 3 study program.”
- Gerber D, et al. Rilparencel renal autologous cell therapy for patients with Stage 3-4 CKD and type 2 diabetes: Results from a phase 2 clinical trial. Abstract #8, ERA 2024, 23–26 May, Stockholm, Sweden.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« The majority of real-world patients with CKD are not eligible for SGLT2 inhibitor trials Next Article
Early phase data show albuminuria improvement with avenciguat »
« The majority of real-world patients with CKD are not eligible for SGLT2 inhibitor trials Next Article
Early phase data show albuminuria improvement with avenciguat »
Table of Contents: ERA 2024
Featured articles
Meet the Experts: Navigating Kidneys and Genes
Chronic Kidney Disease
FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease
Early phase data show albuminuria improvement with avenciguat
Rilparencel leads to kidney function stabilisation in chronic kidney disease and type 2 diabetes
The majority of real-world patients with CKD are not eligible for SGLT2 inhibitor trials
Kidney Transplantation and Dialysis
CD38 inhibition by felzartamab promising for resolution of antibody-mediated rejection following kidney allografts
TATH trial: Twice-weekly haemodialysis can be an alternative to thrice weekly regimen
KIR-HLA class I mismatch could be involved in antibody-mediated rejection of transplanted kidneys
IgA Nephropathy
Atrasentan shows positive interim results in IgA nephropathy: ALIGN phase 3 trial
Zigakibart slows down eGFR decline in IgA nephropathy
Long-term atacicept shows continued benefit in IgA nephropathy
APPLAUSE-IgAN: Iptacopan improves proteinuria in IgA nephropathy
Cardio-Renal Interplay
Semaglutide improves renal outcomes in overweight/obese participants with cardiovascular disease and no diabetes
Discrepancy between cardiovascular RCT participants and real-life CKD patients could limit generalisability of RCT results
MERCURI-1: Perioperative empagliflozin shows renal protection following cardiac surgery
Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes
Other Nephrology
Preview of the new KDIGO Guidelines for ADPKD, available later in 2024
APPEAR-C3G: Iptacopan shows promise for complement 3 glomerulopathy
Anti-nephrin autoantibody positivity describes a unique subclass of podocytopathies
Active vitamin D plus low-dose prednisolone is an alternative to high-dose prednisolone in minimal change disease
Claudin-1 is a potential antibody target for crescent glomerulonephritis
Rituximab protocol based on PLA2R1 epitope spreading outperforms the standard GEMRITUX protocol in membranous nephropathy
The REACT score predicts relapse in ANCA-associated vasculitis
Related Articles
November 28, 2023
New approaches to successful vascular access
June 5, 2024
Meet the Experts: Navigating Kidneys and Genes
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com